Carvolix
5.94
EUR
+0.06
(+1.02%)
Carvolix
GETTEX:0JZ
(Gettex)
Recent
price
5.94
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
EUR
•
in mil. unless spec.Working Capital
EUR
•
in mil. unless spec.Growth Rates
EUR
•
in mil. unless spec.Semi-annual Revenue
EUR
•
in mil. unless spec.Semi-annual Earnings Per Share
EUR
•
in mil. unless spec.Semi-annual Dividends Per Share
EUR
•
in mil. unless spec.- Similar Companies
- Business
- Carvolix S.A. is a French medical technologies company that develops AI-driven nano-robotic systems and biomimetic implants to treat structural heart diseases and stroke risks. The company operates at the commercial and clinical stages with a focus on enabling interventional cardiology procedures and neurovascular interventions through imaging-guided mini-robots and biomimetic valve solutions. Headquartered in Aix-en-Provence, France, Carvolix was founded in 2011 and is listed on Euronext Paris under the CVX ticker (formerly Affluent Medical), with ongoing activities aimed at expanding access to advanced minimally invasive therapies globally. Main products and services - AI-driven mini-robots for interventional cardiology: imaging-guided mechanisms designed to assist structural heart disease procedures, including autonomous or semi-autonomous robotic assistance to clinicians during complex mitral and other valvular interventions. - Biomimetic heart valves and valve-related implants: biomimetic prosthetic components and related devices intended to replace or support diseased heart valves, with a focus on safer, less invasive delivery. - Neurovascular and stroke-treatment devices: miniature robotic platforms and compatible implants aimed at enhancing endovascular treatment of cerebrovascular conditions and stroke-related procedures. - Implantable biomimetic actuators and sphincter technologies (where applicable to their portfolio): miniaturized actuators designed to restore or mimic physiological functions in targeted organs. - Imaging and software solutions: AI-driven imaging analytics, planning tools, and procedural guidance software to support clinicians during device deployment and therapy optimization. Latest major company changes - Strategic alliances and partnerships: engages in collaborations with medical technology partners and clinical research organizations to advance AI-enabled robotic platforms and biomimetic devices for structural heart disease and stroke treatment. - Funding and corporate developments: pursues financing rounds and strategic investments to advance product development, regulatory pathways, and commercialization, including initiatives to broaden access in international markets. - Product launches and service expansions: introduces and refines AI-imaging driven mini-robot platforms and companion valve implants to address unmet clinical needs in interventional cardiology and neurointerventions. - Corporate reorganizations and branding: previously operated under the Affluent Medical umbrella with a rebranding to Carvolix as part of corporate strategy to emphasize autonomous robotic solutions and biomimetic devices across cardiovascular and neurological therapies. - Geographic and operational expansion: expands clinical activities and partnerships across Europe, with continued exploration of partnerships in North America and other regions to scale adoption. Additional context - Industry and segments: medical devices and digital health; structural heart, neurovascular, and interventional robotics. - Target markets: interventional cardiology centers, cardiac surgery departments, and specialized neurointerventional facilities; hospitals and clinics focused on minimally invasive therapies. - Geographic footprint: primarily Europe (notably France) with active considerations for North American and other global markets through partnerships, clinical trials, and distribution networks. - Corporate relationships: operates as an independent company with history linked to Affluent Medical; strategic alignment with health-tech investors and venture backers to advance AI-enabled medical robotics. - Subsidiaries and parent: operates as Carvolix S.A. in France, with historical ties to Affluent Medical branding and corporate lineage; no public information indicating a parent company beyond its listed corporate structure.